September 20, 2019

Robert Fried
Chief Executive Officer
ChromaDex Corporation
10900 Wilshire Blvd., Suite 650
Los Angeles, California 90024

       Re: ChromaDex Corporation
           Registration Statement on Form S-3
           Filed September 12, 2019
           File No. 333-233729

Dear Mr. Fried:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this comment, we may have additional comments.

Registration Statement on Form S-3 filed September 12, 2019

General

1.     We note that the forum selection provision in Article XI of your Amended
and Restated
       Bylaws identifies the Court of Chancery of the State of Delaware as the
exclusive forum
       for certain litigation, including any "derivative action." Please
disclose whether this
       provision applies to actions arising under the Securities Act or
Exchange Act. In that
       regard, we note that Section 27 of the Exchange Act creates exclusive
federal jurisdiction
       over all suits brought to enforce any duty or liability created by the
Exchange Act or the
       rules and regulations thereunder, and Section 22 of the Securities Act
creates concurrent
       jurisdiction for federal and state courts over all suits brought to
enforce any duty or
       liability created by the Securities Act or the rules and regulations
thereunder. If the
       provision applies to Securities Act claims, please also revise your
prospectus to state that
       there is uncertainty as to whether a court would enforce such provision
and that investors
 Robert Fried
ChromaDex Corporation
September 20, 2019
Page 2
      cannot waive compliance with the federal securities laws and the rules
and regulations
      thereunder. If this provision does not apply to actions arising under the
Securities Act or
      Exchange Act, please tell us how you will inform investors in future
filings that the
      provision does not apply to any actions arising under the Securities Act
or Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Irene Paik at 202-551-6553 or Mary Beth Breslin at
202-551-3625 with
any other questions.



                                                            Sincerely,
FirstName LastNameRobert Fried
                                                            Division of
Corporation Finance
Comapany NameChromaDex Corporation
                                                            Office of
Healthcare & Insurance
September 20, 2019 Page 2
cc:       Matt Robbins - Cooley LLP
FirstName LastName